CD274 and head and neck squamous cell carcinoma: The correlation between FDA approval for these immunotherapy drugs in HNSCC and PD-L1 expression underscores the pivotal role of PD-L1 as a predictive marker, making it the most widely used biomarker in clinical practice (83).